Characterizing an alternatively spliced NTRK2 isoform in development and cancer
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
批准号:
10490261
负责人:
Siobhan Pattwell
金额:
$18.71万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-24 至 2024-08-31
关键词:
AddressAgeAlternative SplicingAnatomyAntibodiesAutomobile DrivingBindingBiologyCancer EtiologyCellsDataDevelopmentDevelopmental ProcessDiagnosticEmbryoEmbryonic DevelopmentErinaceidaeEventFoundationsFutureGliomaGoalsHumanIn VitroLeadLentivirus VectorLifeLightLinkMaintenanceMalignant NeoplasmsMolecularMusMutagenesisNTRK2 geneNeoplasm MetastasisNerve Growth Factor ReceptorsNervous system structureNeurophysiology - biologic functionOncogenesOncogenicOrganOrganogenesisPTEN genePathway interactionsPatternPhosphotransferasesPlatelet-Derived Growth FactorProcessProtein IsoformsProteinsRNA SplicingReagentRoleSeriesSignal PathwaySignal TransductionTherapeuticTimeTissuesTranscriptTumor BiologyVariantWorkcancer initiationcancer typecareercombinatorialcourse developmentexperimental studyin vitro activityin vivoindexingloss of functionmembermouse modelneglectnerve stem cellneurodevelopmentneurotrophic factornotch proteinnovelnovel diagnosticsoverexpressionpostnatalpostnatal developmentreceptorsynaptic pruningtherapeutic targettranscriptome sequencingtumortumorigenesisvector
中文摘要
项目摘要/摘要
长期以来,发育信号与癌症的启动、维持和转移之间的联系一直是
因WNT、Hedgehog和Notch路径的几个成员而闻名。可能性仍然是一个
发育调节的剪接事件可能与这些致癌途径有相似的特征,驱动
在解剖学上适当的、有时间限制的情况下的正常发育,并在以下情况下导致癌症
监管不力。我们最近发现了一种缺乏激酶的NTRK2神经营养因子受体剪接变异体,
TrkB.T1在胶质瘤中占主导地位,并放大了几个致癌信号通路。我们的初步数据
提示TrkB.T1是胚胎发育过程中在多个器官中主要表达的NTRK2亚型
在人类的各种癌症类型中高度表达,当过度表达时结合起来
随着PTEN的丢失,会在小鼠中引起广泛的癌症。这里提出的项目旨在描述
利用一种新的抗体和一种新的小鼠模型显示TrkB.T1在发育和癌症中的作用
当剪接变体出生后在表达它们的特定器官中过度表达时,就是致癌的。
在开发过程中。通过干扰细胞特异性TrkB.T1剪接变体在小鼠中的表达,胚胎和
利用单细胞组合索引RNA测序分析跟踪NTRK2转录本在胚胎中的表达
和出生后发育,我的目标是(1)将发育机制和剪接选择与癌症联系起来,(2)将
一种信号增加的蛋白,以及(3)试图辨别是否将细胞困在一个特定的
发育状态会导致癌症。通过进一步描述TrkB.T1发挥作用的机制,
这些项目有可能为多种癌症的诊断和治疗开辟新的途径。
类型。这里提出的实验建立在我之前在神经发育、神经营养因子生物学、
和癌症,并将有助于为我的长期职业目标奠定基础,这些目标的中心是雇用一名
研究神经营养对肿瘤生物学的贡献和发现的发展指导方法
发育对肿瘤发生的影响。
英文摘要
Project Summary/Abstract
The link between developmental signaling and cancer initiation, maintenance and metastasis has long been
known for several members of the Wnt, Hedgehog, and Notch pathways. The possibility remains that a
developmentally-regulated splicing event may share similar features with these oncogenic pathways, driving
normal development in an anatomically appropriate, temporally restricted context, and causing cancer when
dysregulated. We have recently shown that a kinase-deficient NTRK2 neurotrophin receptor splice variant,
TrkB.T1, predominates in glioma and amplifies several oncogenic signaling pathways. Our preliminary data
suggest that TrkB.T1 is the predominate NTRK2 isoform expressed across multiple organs during embryonic
development, is highly expressed in various cancer types in humans, and when over-expressed in combination
with PTEN loss, causes a wide range of cancers in mice. The project proposed here seeks to characterize the
role TrkB.T1 in development and cancer using a novel antibody and a novel mouse model to show that specific
splice variants are oncogenic when overexpressed, postnatally, in the specific organs that expressed them
during development. By perturbing cell-specific TrkB.T1 splice variant expression in mice, embryonically, and
using single cell combinatorial indexing RNA-sequencing analysis to follow NTRK2 transcripts across embryonic
and postnatal development, I aim to (1) link developmental mechanisms and splicing choices to cancer, (2) link
a kinase deficient protein with increases in signaling, and (3) seek to discern whether trapping cells in a particular
developmental state can lead to cancer. By further characterizing the mechanism by which TrkB.T1 functions,
these projects have the potential to open new avenues for diagnostic and therapeutic targets for multiple cancer
types. The experiments proposed here build upon my previous work in neurodevelopment, neurotrophin biology,
and cancer and will help set the stage for my long-term career goals which center around employing a
developmentally guided approach to studying neurotrophic contributions to tumor biology and uncovering
developmental influences on oncogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
-
批准号:10855131
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2023
-
负责人:Siobhan Pattwell
-
依托单位:
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
-
批准号:10191906
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2021
-
负责人:Siobhan Pattwell
-
依托单位:
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
-
批准号:10688049
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2021
-
负责人:Siobhan Pattwell
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: